Point72 Asset Management L.P. boosted its holdings in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 16.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,856,750 shares of the company's stock after purchasing an additional 256,010 shares during the quarter. Point72 Asset Management L.P. owned approximately 3.28% of Design Therapeutics worth $11,456,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of DSGN. Driehaus Capital Management LLC purchased a new position in Design Therapeutics during the fourth quarter worth approximately $4,788,000. MPM Bioimpact LLC purchased a new position in shares of Design Therapeutics in the fourth quarter valued at approximately $3,452,000. Dimensional Fund Advisors LP lifted its position in shares of Design Therapeutics by 60.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 215,265 shares of the company's stock valued at $1,328,000 after acquiring an additional 80,905 shares in the last quarter. Walleye Capital LLC lifted its position in shares of Design Therapeutics by 101.6% in the fourth quarter. Walleye Capital LLC now owns 141,127 shares of the company's stock valued at $871,000 after acquiring an additional 71,127 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Design Therapeutics by 15.2% in the fourth quarter. Northern Trust Corp now owns 388,125 shares of the company's stock valued at $2,395,000 after acquiring an additional 51,351 shares in the last quarter. Hedge funds and other institutional investors own 56.64% of the company's stock.
Design Therapeutics Stock Down 1.6%
Shares of NASDAQ DSGN traded down $0.06 during midday trading on Friday, hitting $3.81. The stock had a trading volume of 184,751 shares, compared to its average volume of 186,308. The company has a market capitalization of $216.29 million, a PE ratio of -4.48 and a beta of 1.77. The stock has a 50 day simple moving average of $3.77 and a 200-day simple moving average of $4.82. Design Therapeutics, Inc. has a 1 year low of $2.60 and a 1 year high of $7.77.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03). As a group, analysts expect that Design Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.
About Design Therapeutics
(
Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Recommended Stories
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
